SavedAdd your journal

Journals / European Journal of Therapeutics / 2018 / Cilt: 24 - Sayı: 1

Point Reached in Targeted Therapy; Where are we?

Havva YEŞİL ÇINKIR
Pages
19–25
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Identification of new molecular targets and development of novel therapies related to activated immune cytotoxic cells are significant steps in achieving the goal of personalized therapy in lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lung cancer is a very important public health problem.
📊
Key Findings & Data:Lung cancer is a very important public health problem.
💡
Conclusion & Impact:Identification of new molecular targets and development of novel therapies related to activated immune cytotoxic cells are significant steps in achieving the goal of personalized therapy in lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lung cancer is a very important public health problem. Identification of new molecular targets and development of novel therapies related to activated immune cytotoxic cells are significant steps in achieving the goal of personalized therapy in lung cancer.

🔖

Cite This Article

ÇINKIR, H. Y. (2022). Point Reached in Targeted Therapy; Where are we?. European Journal of Therapeutics, Cilt: 24 - Sayı: 1, 19–25. https://ajindex.com/articles/512326

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Yüce D, Kılıçkap S. Epidemiology and Etiology. Turkiye Klinikleri Radiat Oncol-Special Topics 2018; 4: 1-7.
  2. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-49. [CrossRef] Griffin R, Robert RA. Molecular Targets in Non-Small Cell Lung Cancer. Ochsner J 2017; 17:388-92.
  3. Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Res 2012; 22: 2101-8. [CrossRef] Weinstein IB. Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 2002; 297: 63-4. [CrossRef] Demir M, Kılıçkap S. Targeted Therapy and Biological Agents. Turkiye Klinikleri Radiat Oncol-Special Topics 2018; 4: 86-92. Puri T. Targeted therapy in nonsmall cell lung cancer. Indian J Cancer 2017; 54: 83-8. [CrossRef] Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9: 154-62. [CrossRef] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. [CrossRef] Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-59. [CrossRef] Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42. [CrossRef] Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46. [CrossRef] Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive nonsmall-cell lung cancer: analyses from the phase III, ran